Every med spa owner I talk to right now is either running a GLP-1 weight loss program or wondering whether they should. The demand is real — J.P. Morgan Research projects roughly 25 million Americans will be on GLP-1 treatment by 2030, up from about 10 million in 2025 — but most of the advice out there covers the marketing and skips the part that actually decides whether the program survives: sourcing, startup costs, pricing, and retention math. I’ve already written about the advertising rules for GLP-1 programs in 2026. This guide is everything that happens before your first patient walks in.
Why GLP-1 is the highest-LTV service line in aesthetics right now
Injectables are episodic. A tox patient comes in every 3–4 months, a filler patient maybe twice a year. A GLP-1 patient pays you every single month — typically $250–$500/month at the program level — for six to eighteen months. That is a fundamentally different revenue shape, and it’s why platforms like Boulevard, in their GLP-1 operations guide for med spas, frame weight loss as a membership-and-workflow business rather than an appointment business.
Run the comparison yourself:
- Tox patient: ~$400 per visit, 3 visits/year = $1,200/year, with each visit requiring a re-booking decision.
- GLP-1 patient: $350/month on membership billing = $4,200/year, with churn — not re-booking — as the only decision point.
There’s also a compounding effect the aesthetics industry has noticed: patients losing 15–20% of body weight start asking about skin laxity, facial volume loss, and body contouring. Boulevard’s guide makes the same point — rapid weight loss creates demand for companion aesthetic services. Your GLP-1 program is a patient-acquisition channel for the rest of your menu.
Sourcing decoded: 503A vs 503B vs branded in 2026
This is where the landscape changed hard, and where most older guides will get you in trouble. Quick history: during the official drug shortages, compounding pharmacies could legally produce copies of semaglutide and tirzepatide. Per FDA announcements, the tirzepatide shortage was declared resolved on December 19, 2024, and the semaglutide shortage on February 21, 2025. Enforcement discretion then wound down — for semaglutide, 503A pharmacies had until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 (per the FDA’s declaratory order and reporting from Pharmacy Times). Courts denied the compounding industry’s injunction attempts, and in 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, with a public comment period that ran through June 29, 2026.
What that means practically:
| Source | 2026 status | Typical clinic economics |
|---|---|---|
| 503A compounded | Legal only for a documented, patient-specific clinical need an approved product can’t meet (e.g., a needed dosage form). Not a volume play anymore. | During the shortage era, clinic acquisition cost ran roughly $40–$120/month per patient (est.); post-enforcement, the eligible patient pool is small and prices are higher. |
| 503B outsourcing | Effectively blocked for GLP-1 copies; FDA’s 2026 bulks-list proposal aims to close this permanently. | Not a viable sourcing strategy for a new program. |
| Branded, manufacturer-direct | The compliant mainstream path. Patients buy through NovoCare Pharmacy (Wegovy) or LillyDirect (Zepbound) self-pay programs. | Per published 2026 self-pay pricing: Zepbound vials $299–$449/month via LillyDirect; Wegovy $199 intro fills then $349–$399/month via NovoCare, with oral Wegovy at $149–$199/month. |
The strategic takeaway: build your program model around branded medication the patient pays for directly, and charge for the clinical program wrapped around it — exams, dosing management, labs, body composition tracking, coaching, and companion treatments. If you do work with a compounding pharmacy for legitimate patient-specific needs, vet it: verify state licensure, ask for the pharmacy’s most recent state board inspection results, confirm API sourcing from FDA-registered facilities, and get their beyond-use dating and sterility testing documentation in writing. If a pharmacy rep dodges any of those questions, walk.
Startup costs, itemized
Here’s a realistic pre-launch budget for an existing med spa adding a weight loss line. All figures are estimates (est.) based on published 2026 market rates:
| Line item | Est. cost | Notes |
|---|---|---|
| Clinical protocols & SOPs | $1,500–$5,000 | Templated protocol packages exist; custom attorney-reviewed protocols cost more and are worth it. |
| Medical director scope expansion | $500–$2,000/month incremental | Weight loss adds prescribing risk, so directors charge more. Published 2026 guides (MedicalDirectorCo, MedSpa Standards) put total med spa medical director fees at roughly $1,500–$8,000/month depending on state and scope. Model your number with my medical director cost estimator. |
| Labs setup | $500–$2,000 | Draw agreements with Quest/Labcorp, or in-house phlebotomy training. Baseline metabolic panels are standard of care. |
| EMR + telehealth platform | $300–$800/month | You need charting, e-prescribing, and compliant video visits. Many aesthetics platforms now bundle this. |
| Body composition equipment | $0–$10,000 | A quality bioimpedance scale ($2,000–$10,000) is optional but dramatically improves retention conversations. |
| Initial supplies | $500–$1,500 | Sharps, injection supplies, teaching kits. Note: with manufacturer-direct sourcing, you carry little or no drug inventory — patients receive medication directly. |
| Staff training | $1,000–$3,000 | Injection teaching, side-effect triage scripts, escalation protocols. |
| Total (excluding ongoing fees) | ~$5,000–$25,000 est. | Lean launch to fully equipped. |
Compared with adding a laser platform ($75,000–$150,000+), the barrier to entry is low. That’s also the problem — everyone in your zip code can launch this, so execution and retention are the moat.
Pricing models: membership, per-injection, or bundled
Three models dominate the market:
- Monthly membership (my recommendation). One flat fee — market pricing for med spa semaglutide programs generally runs $200 to $500+/month, with many programs starting around $199–$299 (per published clinic pricing surveys) — covering visits, dose management, and check-ins, with medication paid separately through NovoCare or LillyDirect. Predictable revenue, clean compliance separation between clinical fees and drug costs.
- Per-injection pricing. $75–$150 per weekly visit. Easy to start, terrible for retention — every visit is a repurchase decision, and patients who learn self-injection stop coming.
- Bundled programs. 3- or 6-month packages at $900–$2,500 (est. market range). Great cash flow up front, but watch your state’s rules on prepaid medical services and refunds, and expect refund requests from patients who get side effects in week two.
Whatever model you choose, put the program fee and the medication cost on separate lines. Patients comparing you to telehealth-only competitors need to see what they’re actually getting for the program fee: a real exam, in-person monitoring, body composition tracking, and a clinical team that answers the phone.
The retention economics: months 4–12 are where the profit lives
Here’s the math most owners miss. Your patient-acquisition cost — ads, front-desk time, the longer initial consult, baseline labs — is loaded into month one. At a $350/month program fee, a patient who churns at month 3 might barely cover what it cost to acquire and onboard them. The margin is in months 4 through 12.
And month 3 is exactly where programs die. That’s when the scale slows down, side effects have annoyed the patient, and the novelty is gone. The clinics that win treat months 2–4 as an active retention campaign: scheduled check-in calls, body composition re-scans that show progress the bathroom scale doesn’t, dose-adjustment conversations, and planned introduction of companion services. Run your own numbers — patient count, program fee, churn rate by month — through my GLP-1 program profit calculator and you’ll see how brutally sensitive annual profit is to the month-3 churn number.
Retention is also an operations problem. A GLP-1 patient who calls with nausea questions and hits voicemail is a churn event in progress — I’ve written about what unanswered calls cost using the missed call calculator, and weight loss patients are the highest-LTV callers you have.
Compliance corner
Short version, because the details are state-specific and I cover the marketing side in depth in the GLP-1 marketing rules guide:
- Good-faith exams are non-negotiable. A GLP-1 prescription requires a documented exam, assessment, and prescribing decision by an MD, DO, NP, or PA. Enforcement in 2025–2026 has specifically targeted “absentee” supervision — states including Georgia (whose medical board issued a May position statement against matchmaker-style supervision platforms) and California (SB 351, corporate-practice enforcement) are pressing on genuine physician involvement, per compliance summaries from MedSpa Standards and Guardian Medical Direction.
- Telehealth rules vary by state. Some states allow a video good-faith exam; others require in-person for initial prescribing. Verify your state’s rules before building a telehealth-heavy funnel, and confirm your medical director’s agreement actually covers weight loss prescribing — many agreements written for tox and filler don’t.
- Advertising restrictions are tightening. No compounded “semaglutide” brand-name bait ads, no guaranteed weight loss claims, and patient testimonials need HIPAA-compliant authorization — I cover exactly how in my guide to HIPAA-compliant testimonials for GLP-1 and hormone clinics. For the broader rulebook, see my med spa advertising compliance guide for 2026.
The 90-day launch marketing playbook
Days 1–30: internal launch. Your existing patient base is your cheapest cohort. Email and SMS announcement, front-desk scripting (“we now offer medically supervised weight loss”), in-room mentions during aesthetic appointments, and a waitlist page. Most spas can fill their first 15–25 program slots without spending a dollar on ads.
Days 31–60: local search and content. Build a dedicated program page that answers pricing, eligibility, and medication-sourcing questions directly — this is what ranks and, increasingly, what gets cited when prospects ask ChatGPT or Google’s AI results “medical weight loss near me.” Structuring pages for that is exactly what answer engine optimization is for. Update your Google Business Profile services, and start weekly educational content — Instagram works well for this if you follow the compliance lines I outline in the med spa Instagram guide.
Days 61–90: paid and partnerships. Once your consult-to-enrollment conversion is proven organically, turn on Google Ads for high-intent local searches (expect LegitScript certification requirements for weight-loss ad categories) and build referral relationships with gyms, OB/GYNs, and primary care practices that don’t want to manage GLP-1 patients themselves. If you’d rather have the whole engine built for you, that’s what my med spa marketing service does.
Want a second set of eyes on this for your clinic? Book a free strategy call or call/text me at +91 97297 12388.
Frequently asked questions
How much does it cost to add a weight loss program to a med spa?
For an existing med spa, plan on roughly $5,000–$25,000 (est.) in startup costs: protocols, medical director scope expansion, labs setup, EMR/telehealth tooling, supplies, and staff training. Ongoing costs are mainly the incremental medical director fee ($500–$2,000/month est.) and platform subscriptions. It’s one of the cheapest service lines in aesthetics to launch — the hard part is retention, not startup capital.
Can my med spa still offer compounded semaglutide in 2026?
Only in narrow cases. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, ending the era of mass compounded copies. A 503A pharmacy can compound only for a documented, patient-specific clinical need an approved product can’t meet, and the FDA has proposed excluding these drugs from the 503B bulks list entirely. Build your program around branded medication via NovoCare and LillyDirect self-pay channels instead.
How much do patients pay for branded GLP-1s without insurance?
Per published 2026 manufacturer pricing: Zepbound single-dose vials run $299–$449/month through LillyDirect’s self-pay program, and Wegovy runs $199 for introductory fills then $349–$399/month through NovoCare, with oral Wegovy at $149–$199/month. Your program fee sits on top of that, so total patient cost typically lands between $450 and $850/month.
What should a med spa charge for a GLP-1 program?
Market pricing for the clinical program (excluding medication) generally falls between $200 and $500/month. A monthly membership model — covering exams, dose management, check-ins, and body composition tracking — outperforms per-injection pricing because it removes the repurchase decision from every visit and makes revenue predictable.
Do GLP-1 patients need a good-faith exam?
Yes, in every state. A licensed prescriber (MD, DO, NP, or PA, depending on state scope rules) must perform and document an exam and assessment before prescribing. Some states allow this via telehealth video; others require the initial exam in person. Regulators in California, Georgia, Texas, Florida, and New York have all moved against rubber-stamp supervision arrangements, so make sure your medical director is genuinely involved and their agreement explicitly covers weight loss.
When does a GLP-1 program become profitable?
At the patient level, usually around months 3–4, once acquisition and onboarding costs are recovered — which means program-level profit depends almost entirely on how many patients you keep past month 3. Model it with your own numbers in my GLP-1 program profit calculator; a 10-point improvement in month-3 retention typically matters more than a $50 price increase.
